103438-85-3

Basic information

• Product Name: 4-fluoro-3-hydroxy-benzaldehyde
• Synonyms: 4-fluoro-3-hydroxy-benzaldehyde;Benzaldehyde, 4-fluoro-3-hydroxy-
• CAS NO: 103438-85-3
• Molecular Formula: C₇H₅FO₂
• Molecular Weight: 140.11
• Mol File: 103438-85-3.mol
• Article Data: 20

Chemical Properties

• Melting Point: 109-110 °C
• Boiling Point: 229.6 °C at 760 mmHg
• Flash Point: 92.6 °C
• Appearance: /
• Density: 1.35 g/cm³
• Vapor Pressure: 0.0457mmHg at 25°C
• Refractive Index: 1.587
• PKA: 7.99±0.10(Predicted)
• CAS DataBase Reference: 4-fluoro-3-hydroxy-benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-fluoro-3-hydroxy-benzaldehyde(103438-85-3)
• EPA Substance Registry System: 4-fluoro-3-hydroxy-benzaldehyde(103438-85-3)

Safety Data

• Hazardous Substances Data: 103438-85-3(Hazardous Substances Data)

Usage

General Description

4-Fluoro-3-hydroxy-benzaldehyde is a chemical compound with the molecular formula C7H5FO2. It is an aromatic aldehyde with a fluorine atom and a hydroxyl group attached to a benzene ring. The compound is commonly used in organic synthesis as a building block for the production of various pharmaceuticals, agrochemicals, and fine chemicals. It is also used as a reagent in the preparation of heterocyclic compounds and other organic molecules. Its unique structural features make it a valuable intermediate in the development of new drugs and materials. Additionally, 4-fluoro-3-hydroxy-benzaldehyde is used in the flavor and fragrance industry, where it imparts a distinctive aroma to various products. Overall, this compound has diverse applications in pharmaceutical, agrochemical, and flavor industries due to its valuable properties and reactivity.

InChI:InChI=1/C7H5FO2/c8-6-2-1-5(4-9)3-7(6)10/h1-4,10H

Upstream product

• 311464-46-7 4-fluoro-3-nitro-benzaldehyde dimethyl acetal 
• 128495-45-4 (4-fluoro-3-methoxy-phenyl)methanol 
• 82846-18-2 4?fluoro-3-methoxybenzoic acid 
• 128495-46-5 4-fluoro-3-methoxybenzaldehyde 

Downstream Products

• 103439-06-1 4-fluorophenylephrine 
• 103438-95-5 2-Amino-1-(3-benzyloxy-4-fluoro-phenyl)-ethanol 
• 103438-99-9 1-(3-Benzyloxy-4-fluoro-phenyl)-2-methylamino-ethanol 
• 103438-98-8 N-[2-(3-Benzyloxy-4-fluoro-phenyl)-2-hydroxy-ethyl]-formamide 
• 1399849-40-1 4-fluoro-3-(3-methoxypropoxy)benzaldehyde 
• 870837-27-7 3-ethoxy-4-fluorobenzaldehyde 

Relevant articles and documents

Benzylideneacetone Derivatives Inhibit Osteoclastogenesis and Activate Osteoblastogenesis Independently Based on Specific Structure-Activity Relationship

(E)-3,4-Dihydroxybenzylideneacetone (compound 1) inhibited receptor activator of NF-κB ligand-induced osteoclastogenesis of C57BL/6 bone marrow monocyte/macrophages with IC50 of 7.8 μM (IC50 of alendronate, 3.7 μM) while stimulating the differentiation of MC3T3-E1 osteoblastic cells, accompanied by the induction of Runt-related transcription factor 2, alkaline phosphatase, and osteocalcin. (E)-4-(3-Hydroxy-4-methoxyphenyl)-3-buten-2-one (compound 2c) showed a dramatically increased osteoclast-inhibitory potency with IC50 of 0.11 μM while sustaining osteoblast-stimulatory activity. (E)-4-(4-Hydroxy-3-methoxyphenyl)-3-buten-2-one (compound 2g) stimulated alkaline phosphatase production 2-fold at 50 μM without changing osteoclast-inhibitory activity, compared with compound 1. Oral administration of compounds 1, 2c, and 2g prevented ovariectomy-induced osteoporosis in ddY mice to a degree proportional to their osteoclastogenesis-inhibitory potencies. The administration of 1 (mg/kg)/d compound 2c ameliorated histomorphometry of osteoporotic bone to a degree comparable with 10 (mg/kg)/d alendronate. Conclusively, the in vitro capacity of a few benzylideneacetone derivatives to inhibit osteoclastogenesis supported by independent osteoblastogenesis activation was convincingly reflected in in vivo management of osteoporosis, suggesting a potential novel therapeutics for osteopenic diseases.

NOVEL COMPOUNDS, USES AND METHODS FOR THEIR PREPARATION

The present disclosure relates to novel compounds HIF-2α inhibitors and pharmaceutical compositions thereof which may be useful in the treatment and/or prevention of various conditions. The present disclosure also provides methods of preparing such HIF-2α inhibitors and compositions, and methods of using the same.

Sanglifehrin Derivatives and Methods for Their Production

There are provided inter alia compounds of formula (I) and (II) and their use in therapy, particularly for the treatment of viral infection.